Format

Send to

Choose Destination
Nat Rev Cancer. 2008 Apr;8(4):268-78. doi: 10.1038/nrc2351.

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

Author information

1
Department of Surgery (Urology), Memorial Sloan-Kettering Cancer Center New York, New York 10065, USA. liljah@mskcc.org

Erratum in

  • Nat Rev Cancer. 2008 May;8(5):403.

Abstract

Testing for prostate-specific antigen (PSA) has profoundly affected the diagnosis and treatment of prostate cancer. PSA testing has enabled physicians to detect prostate tumours while they are still small, low-grade and localized. This very ability has, however, created controversy over whether we are now diagnosing and treating insignificant cancers. PSA testing has also transformed the monitoring of treatment response and detection of disease recurrence. Much current research is directed at establishing the most appropriate uses of PSA testing and at developing methods to improve on the conventional PSA test.

PMID:
18337732
DOI:
10.1038/nrc2351
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center